scispace - formally typeset
R

Robert Farinotti

Researcher at University of Paris-Sud

Publications -  199
Citations -  5947

Robert Farinotti is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: Pharmacokinetics & High-performance liquid chromatography. The author has an hindex of 40, co-authored 199 publications receiving 5628 citations. Previous affiliations of Robert Farinotti include University of Paris & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

TL;DR: The impact of the patient’s physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed, and limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chlorquine metabolism.
Journal ArticleDOI

In vitro metabolism of chloroquine: identification of cyp2c8, cyp3a4, and cyp2d6 as the main isoforms catalyzing n-desethylchloroquine formation

TL;DR: CQ N-desethylation was diminished when coincubated with quercetin, ketoconazole, or troleandomycin and was strongly inhibited by a combination of ketconazole and quercETin, which further corroborates the contribution of CYP2C8 and CYP3As.
Journal ArticleDOI

P-glycoprotein expression of the human placenta during pregnancy.

TL;DR: As P-glycoprotein appears to be involved in drug extrusion, these data suggest that the placenta's ability to protect the fetus from xenobiotics is greater in early pregnancy than at term.
Journal ArticleDOI

Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients

TL;DR: The number of days postoperation and corticosteroid dose were significant covariates influencing tacrolimus clearance, and the one compartment open model with linear absorption and elimination adequately described the data.
Journal ArticleDOI

Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood

TL;DR: Evaluated sedative, antibiotic and immunosuppressive drug loss in ECMO circuit using ex-vivo and in-vitro experiments observed important losses of propofol and midazolam, while cyclosporine concentration decreased slowly and moderately, and vancomycin concentration remained unchanged in the ex- vivo EC MO circuit primed with whole human blood.